Acadia's $ACAD presentation spooked investors because the company said it expects some short-term bumpiness. This selling is a result of shorts building a big position. $12 next? $ACAD, ACADIA Pharmaceuticals Inc. / H1 User @Paul77777 writes:My 11 year old son is on this drug and it has been a miracle for him. He was lost in his own mind for two years and this drug brought him back after spending two years trying many of the 2nd generation of antipsychotics. Two years of horrible side effects and minor improvement at best. Nuplazid has caused no noticeable side affects and our son is laughing, talking and playing with other kids again. His two doctors said they have never seen a drug have such a positive impact on someone with such sever symptoms. If this drug can do for others what it has done for my son, this will be a blockbuster. I wonder if those who distort the facts regarding the safety of this drug realize that it impacts real people? How many could benefit but don't because of biased shorts, media and politicians like to spin the negative for their own benefit. Here is what the company says regarding the safety of the drugs and what they post is based on facts:"From Acadia:"In a statement, the company says the overall mortality rate for the drug is 12.4/100 patient years, less than half of overall mortality rate of 28.2/100 patient years in people with PDP. "Buy $ACAD when the stock bottoms.